Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

Summary

This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as they experience clinical benefit from it. The purpose of this study is to learn if Zanzalinitib is effective in treating metastatic castrate-resistant prostate cancer.

Timeline

Start

2026-09

Primary completion

2029-05

Completion

2030-05

Drugs

Indications